非普拉宗治疗骨关节炎：每日两次与每日三次给药方案的比较
Feprazone in osteoarthritis: comparison of twice and 3-times daily dosage regimens.
作者信息
Laurent M R, Berry D, Grahame R
出版信息
Pharmatherapeutica. 1983;3(6):393-7.
PMID:6353430
Abstract
In a double-blind crossover trial, 200 mg feprazone 3-times a day was compared with 200 mg twice a day in the treatment of osteoarthritis. There was no difference in clinical efficacy or in adverse effects between the two dosage schedules. Because of its long elimination half-life (approximately 24 hours) it is suggested that feprazone should be given in twice daily dosage and is a simple and effective treatment for osteoarthritis.
摘要
在一项双盲交叉试验中，对每天服用3次、每次200毫克非普拉宗与每天服用2次、每次200毫克治疗骨关节炎的效果进行了比较。两种给药方案在临床疗效和不良反应方面均无差异。由于其消除半衰期长（约24小时），建议非普拉宗采用每日2次给药方案，这是一种治疗骨关节炎的简单有效的方法。
相似文献
1
Feprazone in osteoarthritis: comparison of twice and 3-times daily dosage regimens.非普拉宗治疗骨关节炎：每日两次与每日三次给药方案的比较
Pharmatherapeutica. 1983;3(6):393-7.
2
3
[Results of an open study and a controlled comparative study of feprazone and naproxen in patients with rheumatoid arthritis or osteoarthrosis (author's transl)].非普拉宗与萘普生治疗类风湿性关节炎或骨关节炎患者的开放性研究及对照比较研究结果（作者译）
Wien Med Wochenschr. 1981 Dec 31;131(23-24):597-601.
4
Feprazone compared with indomethacin in the management of rheumatoid arthritis.联苯乙酸与吲哚美辛治疗类风湿关节炎的比较。
Practitioner. 1975 Jul;215(1285):94-7.
5
The disposition of feprazone and its hydroxylated metabolite in human volunteers.非普拉宗及其羟基化代谢产物在人类志愿者体内的处置情况。
Xenobiotica. 1988 Jul;18(7):857-68. doi: 10.3109/00498258809041724.
6
[Clinical evaluation of feprazone in rheumatoid arthritis (author's transl)].非普拉宗治疗类风湿关节炎的临床评价（作者译）
Ryumachi. 1979 Apr;19(2):147-63.
7
A double-blind trial of feprazone in osteoarthritis of the hip.非普拉宗治疗髋关节骨关节炎的双盲试验。
Curr Med Res Opin. 1977;4(9):665-9. doi: 10.1185/03007997709115289.
8
Benoxaprofen: once a day vs twice a day in patients with rheumatoid arthritis or osteoarthritis.苯恶洛芬：类风湿性关节炎或骨关节炎患者每日一次与每日两次用药对比
J Rheumatol Suppl. 1980;6:68-75.
9
10
[Topical treatment of thrombophlebitis with feprazone and benzydamine. Controlled clinical study].[用非普拉宗和苄达明局部治疗血栓性静脉炎。对照临床研究]
Minerva Med. 1976 Mar 24;67(14):880-4.
引用本文的文献
1
Feprazone Ameliorates TNF-α-Induced Loss of Aggrecan via Inhibition of the SOX-4/ADAMTS-5 Signaling Pathway.非普拉宗通过抑制SOX-4/ADAMTS-5信号通路改善肿瘤坏死因子-α诱导的聚集蛋白聚糖丢失。
ACS Omega. 2021 Mar 12;6(11):7638-7645. doi: 10.1021/acsomega.0c06212. eCollection 2021 Mar 23.
Zotero 插件